Indian Pharma Market Overview: Ajanta Pharma Ltd. and Industry Insights
Market Growth Analysis
The Indian pharmaceutical market witnessed moderate growth in September, with sales rising by 5.3% compared to the previous year. This growth was slightly lower than the 6.3% increase recorded in August but higher than the 2.1% growth seen a year ago. Overall, the growth in September was attributed to a 5.3% rise in prices and a 2.4% boost from new product launches. However, volume growth remained weak and witnessed a 2.4% drop.
Performance by Key Players
- Indoco Remedies Ltd. emerged as a standout with an 11.5% growth.
- Cipla Ltd. posted a strong 10.8% increase.
- Torrent Pharmaceuticals Ltd. witnessed a 9.7% growth.
- Other companies that performed well include Alkem Laboratories Ltd. (8.1%), GlaxoSmithKline Pharmaceuticals Ltd. (8%), and Ajanta Pharma Ltd. (7.8%).
- Notable mentions include Eris Lifesciences Ltd. (7.1%) and Mankind Pharma Ltd. (6.9%).
Challenges for Other Companies
Some companies underperformed compared to the market. Dr. Reddy’s Laboratories Ltd. reported a modest 3.4% growth, while Abbott India Ltd. and FDC Ltd. posted similar results with 3.3% and 3.2% YoY growth, respectively. Lupin Ltd. lagged further behind at 2.7%, while Pfizer Ltd. and Alembic Pharmaceuticals Ltd. witnessed declines in growth, reporting -5.7% and -6% respectively, marking a challenging year for these companies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.